Sollinda Capital Management LLC Sells 15,866 Shares of Abbott Laboratories $ABT

Sollinda Capital Management LLC cut its stake in Abbott Laboratories (NYSE:ABT) by 90.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,713 shares of the healthcare product maker’s stock after selling 15,866 shares during the quarter. Sollinda Capital Management LLC’s holdings in Abbott Laboratories were worth $229,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. IMG Wealth Management Inc. lifted its stake in Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares during the period. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter valued at $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $31,000. Anfield Capital Management LLC raised its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. 75.18% of the stock is currently owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO personally invested roughly $2M while the stock has been under pressure — a management buy that signals confidence to shareholders and can help stabilize sentiment. Article Title
• Positive Sentiment: Freedom Capital upgraded ABT to a Buy (recently lowering its PT to $120), which gives the stock a retail/institutional buying narrative despite the lower target. Article Title
• Positive Sentiment: Long‑term bull case pieces note Abbott’s Dividend Aristocrat status, multi‑year revenue growth and strong balance sheet, reinforcing a buy-and-hold thesis for income/quality investors. Article Title
• Positive Sentiment: Opinion/bull-case coverage outlines structural upside from diagnostics and recurring revenue streams, offering a narrative that could attract growth‑oriented buyers. Article Title
• Neutral Sentiment: Abbott’s deal with Exact Sciences is reshaping its diagnostics footprint (strategic upside), but its nutrition business is undergoing a reset — a mixed development that likely means longer lead times before clear earnings upside. Article Title
• Neutral Sentiment: Barclays trimmed its price target from $169 to $142 but kept an Overweight rating, signaling conviction in Abbott’s story despite near-term headwinds. Article Title
• Neutral Sentiment: Valuation comparisons (e.g., Zacks piece on NVST vs ABT) highlight Abbott as a relatively lower-volatility, dividend-oriented option — useful context but not an immediate catalyst. Article Title
• Negative Sentiment: Daiwa cut its price target to $113 — a downgrade that adds selling pressure from analysts and may weigh on near‑term sentiment. Article Title
• Negative Sentiment: Leerink lowered its target to $119, another analyst haircut that contributes to a chorus of reduced near‑term expectations. Article Title

Abbott Laboratories Stock Performance

ABT opened at $109.51 on Tuesday. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The firm has a market capitalization of $190.43 billion, a PE ratio of 29.44, a PEG ratio of 1.74 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm’s 50-day moving average price is $122.41 and its 200 day moving average price is $127.35.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the company posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Royal Bank Of Canada dropped their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Barclays decreased their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday. Piper Sandler cut their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Finally, Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.